Skip to main content
Top
Published in: Lung 2/2010

Open Access 01-04-2010

Undifferentiated Connective Tissue Disease-Associated Interstitial Lung Disease: Changes in Lung Function

Authors: Brent W. Kinder, Cyrus Shariat, Harold R. Collard, Laura L. Koth, Paul J. Wolters, Jeffrey A. Golden, Ralph J. Panos, Talmadge E. King Jr.

Published in: Lung | Issue 2/2010

Login to get access

Abstract

Undifferentiated connective tissue disease (UCTD) is a distinct clinical entity that may be accompanied by interstitial lung disease (ILD). The natural history of UCTD-ILD is unknown. We hypothesized that patients with UCTD-ILD would be more likely to have improvement in lung function than those with idiopathic pulmonary fibrosis (IPF) during longitudinal follow-up. We identified subjects enrolled in the UCSF ILD cohort study with a diagnosis of IPF or UCTD. The primary outcome compared the presence or absence of a ≥5% increase in percent predicted forced vital capacity (FVC) in IPF and UCTD. Regression models were used to account for potential confounding variables. Ninety subjects were identified; 59 subjects (30 IPF, 29 UCTD) had longitudinal pulmonary function data for inclusion in the analysis. After accounting for baseline pulmonary function tests, treatment, and duration between studies, UCTD was associated with substantial improvement in FVC (odds ratio = 8.23, 95% confidence interval, 1.27–53.2; p = 0.03) during follow-up (median, 8 months) compared with IPF. Patients with UCTD-ILD are more likely to have improved pulmonary function during follow-up than those with IPF. These findings demonstrate the clinical importance of identifying UCTD in patients presenting with an “idiopathic” interstitial pneumonia.
Literature
1.
go back to reference Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G et al (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81(2):139–153CrossRef Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G et al (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81(2):139–153CrossRef
2.
go back to reference Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR et al (2001) Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 164(7):1182–1185PubMed Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR et al (2001) Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 164(7):1182–1185PubMed
3.
go back to reference Kocheril SV, Appleton BE, Somers EC, Kazerooni EA, Flaherty KR, Martinez FJ et al (2005) Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum 53(4):549–557CrossRefPubMed Kocheril SV, Appleton BE, Somers EC, Kazerooni EA, Flaherty KR, Martinez FJ et al (2005) Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum 53(4):549–557CrossRefPubMed
4.
go back to reference Hubbard R, Venn A (2002) The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 41(6):676–679CrossRef Hubbard R, Venn A (2002) The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford) 41(6):676–679CrossRef
5.
go back to reference Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG et al (2007) Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 175(7):705–711CrossRefPubMed Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG et al (2007) Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 175(7):705–711CrossRefPubMed
6.
go back to reference Bodolay E, Csiki Z, Szekanecz Z, Ben T, Kiss E, Zeher M et al (2003) Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 21(3):313–320PubMed Bodolay E, Csiki Z, Szekanecz Z, Ben T, Kiss E, Zeher M et al (2003) Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 21(3):313–320PubMed
7.
go back to reference Williams HJ, Alarcon GS, Joks R, Steen VD, Bulpitt K, Clegg DO et al (1999) Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol 26(4):816–825PubMed Williams HJ, Alarcon GS, Joks R, Steen VD, Bulpitt K, Clegg DO et al (1999) Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol 26(4):816–825PubMed
8.
go back to reference Danieli MG, Fraticelli P, Salvi A, Gabrielli A, Danieli G (1998) Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. Clin Rheumatol 17(3):195–201CrossRefPubMed Danieli MG, Fraticelli P, Salvi A, Gabrielli A, Danieli G (1998) Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. Clin Rheumatol 17(3):195–201CrossRefPubMed
9.
go back to reference Mosca M, Tavoni A, Neri R, Bencivelli W, Bombardieri S (1998) Undifferentiated connective tissue diseases: the clinical and serological profiles of 91 patients followed for at least 1 year. Lupus 7(2):95–100CrossRefPubMed Mosca M, Tavoni A, Neri R, Bencivelli W, Bombardieri S (1998) Undifferentiated connective tissue diseases: the clinical and serological profiles of 91 patients followed for at least 1 year. Lupus 7(2):95–100CrossRefPubMed
10.
go back to reference Clegg DO, Williams HJ, Singer JZ, Steen VD, Schlegel S, Ziminski C et al (1991) Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. J Rheumatol 18(9):1340–1343PubMed Clegg DO, Williams HJ, Singer JZ, Steen VD, Schlegel S, Ziminski C et al (1991) Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. J Rheumatol 18(9):1340–1343PubMed
11.
go back to reference Mosca M, Tani C, Neri C, Baldini C, Bombardieri S (2006) Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev 6(1):1–4CrossRefPubMed Mosca M, Tani C, Neri C, Baldini C, Bombardieri S (2006) Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev 6(1):1–4CrossRefPubMed
12.
go back to reference Mosca M, Neri R, Bombardieri S (1999) Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 17(5):615–620PubMed Mosca M, Neri R, Bombardieri S (1999) Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 17(5):615–620PubMed
13.
go back to reference Doria A, Mosca M, Gambari PF, Bombardieri S (2005) Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both? J Rheumatol 32(2):213–215PubMed Doria A, Mosca M, Gambari PF, Bombardieri S (2005) Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both? J Rheumatol 32(2):213–215PubMed
14.
go back to reference Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B et al (2007) Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 176(7):691–697CrossRefPubMed Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B et al (2007) Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med 176(7):691–697CrossRefPubMed
15.
go back to reference Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR et al (1998) Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 157:199–203PubMed Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR et al (1998) Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 157:199–203PubMed
16.
go back to reference Nicholson AG, Colby TV, Dubois RM, Hansell DM, Wells AU (2000) The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162:2213–2217PubMed Nicholson AG, Colby TV, Dubois RM, Hansell DM, Wells AU (2000) The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 162:2213–2217PubMed
17.
go back to reference American Thoracic Society/European Respiratory Society (2002) International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165:277–304 American Thoracic Society/European Respiratory Society (2002) International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 165:277–304
18.
go back to reference Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG et al (2003) Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 167(7):962–969CrossRefPubMed Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG et al (2003) Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 167(7):962–969CrossRefPubMed
19.
go back to reference King TE Jr, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G et al (2005) Analyses of efficacy end points in a controlled trial of interferon-{gamma}1b for idiopathic pulmonary fibrosis. Chest 127(1):171–177CrossRefPubMed King TE Jr, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G et al (2005) Analyses of efficacy end points in a controlled trial of interferon-{gamma}1b for idiopathic pulmonary fibrosis. Chest 127(1):171–177CrossRefPubMed
20.
go back to reference Travis WD, Hunninghake G, King TE Jr, Lynch DA, Colby TV, Galvin JR et al (2008) Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med 177(12):1338–1347CrossRefPubMed Travis WD, Hunninghake G, King TE Jr, Lynch DA, Colby TV, Galvin JR et al (2008) Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med 177(12):1338–1347CrossRefPubMed
21.
go back to reference Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH et al (2002) Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 19(2):275–283CrossRefPubMed Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH et al (2002) Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 19(2):275–283CrossRefPubMed
22.
go back to reference Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr et al (2005) The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 142(12 Pt 1):963–967PubMed Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr et al (2005) The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 142(12 Pt 1):963–967PubMed
23.
go back to reference King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA et al (2008) BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177(1):75–81CrossRefPubMed King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA et al (2008) BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 177(1):75–81CrossRefPubMed
24.
go back to reference Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R et al (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174(7):795–802CrossRefPubMed Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R et al (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174(7):795–802CrossRefPubMed
25.
go back to reference Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655–2666CrossRefPubMed Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655–2666CrossRefPubMed
26.
go back to reference Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962–3970CrossRefPubMed Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962–3970CrossRefPubMed
27.
go back to reference DuBois R, Albera C, Bradford WZ, Costabel U, Hormel P, King Jr TE et al (2009) Predictors of mortality in patients with idiopathic pulmonary fibrosis. In: American Thoracic Society international conference, San Diego, California DuBois R, Albera C, Bradford WZ, Costabel U, Hormel P, King Jr TE et al (2009) Predictors of mortality in patients with idiopathic pulmonary fibrosis. In: American Thoracic Society international conference, San Diego, California
28.
go back to reference Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ, Lynch JP 3rd (2004) Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 64(4):405–430CrossRefPubMed Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ, Lynch JP 3rd (2004) Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs 64(4):405–430CrossRefPubMed
29.
go back to reference Thannickal VJ, Flaherty KR, Martinez FJ, Lynch JP 3rd (2004) Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. Expert Opin Pharmacother 5(8):1671–1686CrossRefPubMed Thannickal VJ, Flaherty KR, Martinez FJ, Lynch JP 3rd (2004) Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. Expert Opin Pharmacother 5(8):1671–1686CrossRefPubMed
30.
go back to reference Brown KK, Raghu G (2004) Medical treatment for pulmonary fibrosis: current trends, concepts, and prospects. Clin Chest Med 25(4):759–772 viiCrossRefPubMed Brown KK, Raghu G (2004) Medical treatment for pulmonary fibrosis: current trends, concepts, and prospects. Clin Chest Med 25(4):759–772 viiCrossRefPubMed
Metadata
Title
Undifferentiated Connective Tissue Disease-Associated Interstitial Lung Disease: Changes in Lung Function
Authors
Brent W. Kinder
Cyrus Shariat
Harold R. Collard
Laura L. Koth
Paul J. Wolters
Jeffrey A. Golden
Ralph J. Panos
Talmadge E. King Jr.
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Lung / Issue 2/2010
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-009-9226-7

Other articles of this Issue 2/2010

Lung 2/2010 Go to the issue